Cargando…
First clinical experience with belzutifan in von Hippel–Lindau disease associated CNS hemangioblastoma
We present two cases of von Hippel–Lindau (VHL) disease-associated hemangioblastomas in the CNS treated with the newly approved HIF-2α inhibitor, belzutifan. The first case is a 31-year-old female with confirmed pathogenic germline VHL mutation who presented with multiple hemangioblastomas. The pati...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Future Medicine Ltd
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280404/ https://www.ncbi.nlm.nih.gov/pubmed/35819008 http://dx.doi.org/10.2217/cns-2022-0008 |